HomeCompareMGLN vs JNJ

MGLN vs JNJ: Dividend Comparison 2026

MGLN yields 2.11% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $7.5K in total portfolio value· pulled ahead in Year 7
10 years
MGLN
MGLN
● Live price
2.11%
Share price
$94.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$241.25
Full MGLN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MGLN vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMGLNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MGLN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MGLN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MGLN
Annual income on $10K today (after 15% tax)
$178.97/yr
After 10yr DRIP, annual income (after tax)
$205.06/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,780.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MGLN + JNJ for your $10,000?

MGLN: 50%JNJ: 50%
100% JNJ50/50100% MGLN
Portfolio after 10yr
$26.5K
Annual income
$2,465.32/yr
Blended yield
9.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MGLN
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MGLN buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMGLNJNJ
Forward yield2.11%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$22.8K$30.3K
Annual income after 10y$241.25$4,689.40
Total dividends collected$2.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MGLN vs JNJ ($10,000, DRIP)

YearMGLN PortfolioMGLN Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,911$210.55$10,592$272.30+$319.00MGLN
2$11,889$214.69$11,289$357.73+$600.00MGLN
3$12,940$218.64$12,123$472.89+$817.00MGLN
4$14,068$222.40$13,141$629.86+$927.00MGLN
5$15,279$225.97$14,408$846.81+$871.00MGLN
6$16,578$229.36$16,021$1,151.60+$557.00MGLN
7← crossover$17,971$232.58$18,122$1,588.22$151.00JNJ
8$19,464$235.63$20,930$2,228.20$1.5KJNJ
9$21,065$238.52$24,792$3,191.91$3.7KJNJ
10$22,781$241.25$30,274$4,689.40$7.5KJNJ

MGLN vs JNJ: Complete Analysis 2026

MGLNStock

Magellan Health, Inc., together with its subsidiaries, provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans; and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Further, it offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. In addition, the company provides services to health plans and managed care organizations, employers, labor unions, third party administrators, state governments, military and governmental agencies, exchanges, brokers, and consultants. Magellan Health, Inc. was incorporated in 1969 and is headquartered in Phoenix, Arizona. As of January 4, 2022, Magellan Health, Inc. operates as a subsidiary of Centene Corporation.

Full MGLN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MGLN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MGLN vs SCHDMGLN vs JEPIMGLN vs OMGLN vs KOMGLN vs MAINMGLN vs ABBVMGLN vs MRKMGLN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.